What clinicians consider when advising against GLP-1 use during breastfeeding Lack of large, controlled lactation safety trials Unknown effects on infant growth or neurodevelopment Uncertainty about effects on milk supply or composition Elective nature of GLP-1 therapy for weight loss Availability of safer alternatives after breastfeeding ends Why FDA and medical guidance remains cautious FDA and specialty guidance emphasize caution during breastfeeding for several consistent reasons: Insufficient data: FDA labeling states there are inadequate data on GLP-1 medication effects in breastfed infants.,, Milk supply unknowns: It is not known whether GLP-1 medications affect milk supply (volume) or milk composition., Infant vulnerability: Early infancy is a sensitive developmental period, increasing caution when medication effects are unknown. Elective vs essential use: For weight management, potential maternal benefit often does not outweigh theoretical infant risk.,, Do semaglutide and tirzepatide pass into breast milk
Against Naltrexone/Bupropion, Tirzepatide demonstrated significant protective associations in specific BMI strata
Wegovy and Qsymia are used in different manners Wegovy and Qsymia are different from each other, and one of the most apparent differences is the manner of administration
Both NAC and cysteine have limited ability to cross the blood-brain barrier (BBB) [111]
It is considered a useful marker, no doubt, but it is still far from outcomes that these fairly young and long-standing diabetic patients actually feel
